logo
Share SHARE
FONT-SIZE Plus   Neg

CACI International Q2 Profit Rises; Lifts FY12 EPS Estimate - Quick Facts

CACI International Inc. (CACI) reported second-quarter net income attributable to the company of $41.1 million or $1.51 per share, compared to $33.2 million or $1.08 per share in the prior year quarter.

Pro forma adjusted net income attributable to the company for the quarter rose to $54.4 million or $2.00 per share from $45.9 million or $1.48 per share in the comparable quarter last year.

On average, 16 analysts polled by Thomson Reuters expected earnings of $1.30 per share for the quarter. Analysts' estimates typically exclude one-time items.

Revenues for the quarter grew 12.2 percent to $973.24 million from $867.28 million last year, while fifteen analysts estimated revenues of $952.78 million for the quarter.

Looking forward to the fiscal year 2012, the company raised its earnings guidance range to $5.72 - $5.94 per share, from the prior estimate of $5.55 - $5.80 per share. Analysts currently estimate earnings of $5.67 per share for the full year.

The company expects its revenue guidance for the full year 2012 to the range of $3,850 million to $4,050 million, same as the prior estimate. Analysts currently estimate revenues of $3.92 billion for the full year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Chipotle Mexican Grill Inc. (CMG) on Monday reported a surge in profit for the first quarter, as revenues climbed 20 percent on new restaurant openings and strong same-restaurant sales. Earnings for the quarter trounced Wall Street expectations, but revenues fell short of estimates, hurt largely... Yahoo reported a plunge in profit, hurt by lower prices for display ads as well as one-time charges. Its results fell short of Street estimates, denoting the challenges CEO Marissa Mayer faces in implementing her turnaround plans at the Internet company. Amgen Inc. (AMGN) on Tuesday reported a surge in profit for the first quarter, as revenues grew 11 percent on better pricing and strong demand with research costs falling. Both earnings and revenues for the quarter trumped analysts' estimates. Moving ahead, the drug maker raised its outlook for the full...
comments powered by Disqus
RELATED NEWS
Trade CACI now with 
Follow RTT